Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
123.5 ^USD	-2.89%		-6.03%	+28.03%

May. 17	Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	MT
May. 14	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	May. 02	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	May. 01	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	May. 01	MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	May. 01	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21	RE
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	Feb. 28	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Prices for new US drugs rose 35% in 2023, more than the previous year	Feb. 23	RE
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data	Feb. 16	MT
US FDA to review Sarepta's Duchenne gene therapy for traditional approval	Feb. 16	RE
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication	Feb. 16	CI
Wegovy packing supplier Catalent lays off 300 workers	Feb. 14	RE
Busy week ahead!	Jan. 29
Sarepta says its experimental Duchenne drug more effective than older medicine	Jan. 29	RE
Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51	Jan. 29	CI
Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4	Jan. 16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Highlights

Filters